Antifungal susceptibility testing is a very dynamic field of medical mycology. Standardization
of in vitro susceptibility tests by the Clinical and Laboratory Standards Institute (CLSI) and …

An increasing number of people is affected by fungal biofilm-based infections, which are
resistant to the majority of currently-used antifungal drugs. Such infections are often caused …

Fungal infections cause more than 1.5 million deaths a year. Due to emerging antifungal
drug resistance, novel strategies are urgently needed to combat life-threatening fungal …

The fractional inhibitory concentration (FIC) index range of 0.5 to 4 that is commonly used to
define additivity results in no interactions in most combination studies of antifungal agents …

As a consequence of the worsening situation with multidrug-resistant (MDR) pathogens and
a disparity in the commercialization of novel antimicrobial agents, scientists have been …

Abstract Background Therapeutic options against Multi Drug Resistant (MDR) pathogens
are limited and the overall strategy would be the development of adjuvants able to enhance …

Objectives Biofilm formation by Candida albicans poses an important therapeutic challenge
in human diseases. Typically, conventional antifungal agents encounter difficulty in treating …

Although many antifungal agents are available in clinical treatment, increasing resistance of
fungi, especially Candida species, to the available drugs requires the development of new …

The spreading of multidrug-resistant Candida auris is considered as an emerging global
health threat. The number of effective therapeutic regimens is strongly limited; therefore …

Aims: Determine whether certain, natural phenolic compounds enhance activity of
commercial antifungal drugs against yeast strains of Candida and Cryptococcus …